San Francisco (ots/PRNewswire) - Novo Nordisk today announced that the PIONEER 6 trial achieved its primary endpoint by demonstrating non-inferiority of major adverse cardiovascular events (MACE) with oral semaglutide compared with placebo, both in addition to standard of care. The primary endpoint was defined as ...
APR Applied Pharma Research s.a.
Balerna, Switzerland (ots/PRNewswire) - APR Applied Pharma Research sa (APR) presented at the recent 29th conference of the European Wound Management Association (EWMA) in Göteborg, the results of a clinical study confirming Nexodyn® AcidOxidizing Solution (AOS) to promote the restart of the healing process in ...
Amsterdam (ots/PRNewswire) - - Rifaximin significantly reduced the incidence of all-cause hospital admissions in HE patients with advanced cirrhosis on the waiting list for liver transplantation - Rifaximin contributed to improved outcomes in HE patients on the waiting list helping patients stay out of hospital for ...
Abstracts 54-OR and 55-OR Secondary data at 52 weeks demonstrated statistically significant blood sugar reductions and statistically significant reduction of body weight vs both Jardiance® and Victoza® San Francisco (ots/PRNewswire) - Findings presented today from two phase 3a clinical trials evaluated oral ...
Geneva (ots) - If they want to win, elite and amateur athletes need to make their oral health a top priority. FDI World Dental Federation (FDI) couldn't agree more. Today the organization released a series of sports dentistry resources for amateur and elite athletes, dentists and sports medicine physicians, and sports organizations. The release coincides with a packed ...
ASCO Abstract # Tepotinib (MET kinase inhibitor): 9005 Not intended for UK- , Canada- or US-based media Darmstadt, Germany (ots/PRNewswire) - - Alterations of the MET signaling pathway are present in 3-5% of non-small cell lung cancer patients and correlate with poor prognosis - New interim data from Phase II ...
- Easy to measure biomarkers could identify a group of patients who benefit even more from ACARIZAX® treatment of house dust mite (HDM)-induced allergic asthma - Early identification of patients would allow earlier treatment intervention - With its HDM SLIT-tablet, ALK is well-placed to lead the way on ...
Prague (ots/PRNewswire) - Zentiva Group a.s. announces the completion of its previously declared acquisition of Romanian-based pharmaceutical company Solacium Pharma, together with its subsidiary, Be Well Pharma. The finalization of this acquisition will play a key role in the long-term growth strategy of Zentiva and will help to better support Romanian consumers' healthcare needs. About Zentiva Zentiva is a European ...
Not intended for media in the UK and the U.S. - Company launches global art campaign for people with MS to express their invisible symptoms and the unseen impact of the disease - Thought-provoking campaign coincides with the launch of MSonyourterms.com (http://www.msonmyterms.com/), a resource for patients, carers, and the public to understand MS from the Inside Out - Merck to donate EUR1 to the Multiple Sclerosis ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- , Canada- or US-based media ASCO Abstract # Bintrafusp alfa (bifunctional fusion protein): TPS9114; Tepotinib (MET kinase inhibitor): 9005; Discovery: 2567; ERBITUX® (cetuximab): 3580; BAVENCIO® (avelumab): 9569; 101; 4552; 4072 - New biomarker analyses ...
Duesseldorf, Germany (ots/PRNewswire) - Dr. Bernd Metzner (48) takes up the position of Chief Financial Officer of Gerresheimer AG on May 15, 2019. Dr. Metzner had been Chief Financial Officer of SDAX-listed Ströer SE & Co. KGaA since 2014. "I very much welcome the financial expertise and years of industry experience that Dr. Bernd Metzner brings to the Management ...
EUR62M funding will be used to progress wholly-owned pipeline products through clinical development and expand manufacturing activities Dr. Guido Guidi, Dr. Roberto Ferraresi and Dr. Roberto Marsella join the board of directors Siena, Italy (ots/PRNewswire) - Philogen S.p.A (or the "Company"), a clinical-stage biotechnology company focused on antibody-based therapeutics, today is pleased to announce a EUR62 million ...
Not intended for U.S. media - 48-week results provide additional evidence of relapse reduction for investigational evobrutinib - Evobrutinib demonstrated rapid lesion reductions on MRI at week 12 that were maintained through week 48, with no new safety signals identified over 52 weeks - Data presented at the ...
Not intended for U.S. or U.K. based media - 20 abstracts will be presented during the AAN Annual Meeting 2019 to demonstrate Merck's commitment and clinical development program in multiple sclerosis Darmstadt, Germany (ots/PRNewswire) - Merck, a leading science and technology company, today announced that data from ...
As part of its ongoing commitment to raising awareness of rosacea and the hidden burden of the disease, Galderma is collaborating with top social media influencers this Rosacea Awareness Month, to encourage people with rosacea to speak up and share experiences of the beyond the visible impact of living with this ...
- Rifaximin-a in combination with lactulose, the standard of care (SOC) treatment resulted in significant reductions ...
- Bempedoic acid is an oral, once-daily ATP citrate lyase (ACL) inhibitor that reduces cholesterol and fatty acid synthesis in the liver - Bempedoic acid significantly reduced LDL-Cholesterol (LDL-C) vs placebo at week 12 (primary endpoint, absolute reduction -36mg/dL, -21,4%) - Over 24-weeks, bempedoic acid was ...
- MAVENCLAD is the first oral MS treatment to provide two years of proven efficacy with a maximum of 20 days of treatment - MAVENCLAD's unique mechanism may provide an important new option for patients with ongoing active disease - MAVENCLAD demonstrated significant efficacy across key measures of disease activity ...
FOR EX-US MEDICAL AND TRADE MEDIA ONLY - T-cell prolymphocytic leukaemia is an extremely rare and aggressive T-cell leukaemia, with very limited effective treatment options1,2 - Tinostamustine is in very early phase clinical trials to investigate it as a potential future treatment option in this area of significant ...
FOR EUROPEAN MEDICAL AND TRADE MEDIA ONLY - Study will enrol 200 adult patients with limb trauma who are rescued by helicopter - Efficacy, tolerability and practicality of use of the inhaled analgesic in hostile mountain environments to be investigated Cambridge, England (ots/PRNewswire) - The Mundipharma network ...
EUR50,000 award goes to Newcastle University, in collaboration with Medical University, Graz and Newcastle Hospitals NHS Foundation Trust Staines-Upon-Thames, England (ots/PRNewswire) - Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, today announced the recipient of 2019's Advancing Extracorporeal Photopheresis (ECP) Immunomodulation ...
Darmstadt, Germany (ots/PRNewswire) - - MAVENCLAD® is now approved in 52 countries worldwide - Approval brings forward new treatment option with a novel mechanism for highly active relapsing multiple sclerosis in Switzerland - Approval based on extensive clinical development program capturing more than 10,000 ...
Darmstadt, Germany (ots/PRNewswire) - - MAVENCLAD® is now approved in 52 countries worldwide - Approval brings forward new treatment option with a novel mechanism for highly active relapsing multiple sclerosis in Switzerland - Approval based on extensive clinical development program capturing more than 10,000 ...
New Orleans (ots/PRNewswire) - Oral semaglutide 7 mg and 14 mg demonstrated superior HbA1c and body weight reductions compared to Januvia® (sitagliptin 100 mg). Non-inferiority for oral semaglutide 3 mg for HbA1c reductions at 26 weeks was not confirmed. Presented today at the Endocrine Society Annual Meeting in ...
Québec, Canada (ots) - GenePOC Inc., member of the Debiopharm Group, announces its third test to be cleared by the FDA, the GenePOC Strep A assay, to be used with the revogene(TM) device. About Group A Streptococcus (GAS) infection GAS is the most common bacterial etiology of pharyngitis accounting for 15 to 30% cases in children and 5 to 20% in adults[1]. In the ...
Paris and Zug, Switzerland (ots/PRNewswire) - Nordic Group, a pharmaceutical company focusing on the development and commercialisation of hospital and orphan products, and Primex Pharmaceuticals AG, an innovative global Anaesthesia pharmaceutical company, announced a strategic agreement today to launch OZALIN® in ...
Not intended for US, Canada and UK-based media Darmstadt, Germany and New York (ots/PRNewswire) - Merck and Pfizer Inc. (NYSE: PFE) today announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study evaluating the efficacy and safety of avelumab in combination with chemotherapy followed by ...
Munich (ots/PRNewswire) - - In 2019, the Edoxaban Clinical Research Programme will deliver new evidence on LIXIANA® (edoxaban) use in clinical practice. EMIT-AF/VTE is one of the first sets of data to be presented - EMIT-AF/VTE is a large observational, multicentre, multinational study on edoxaban peri-procedural ...